Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

BofA hails NatWest's 'sustainable quality' after Q4 profit beat

(Sharecast News) - Bank of America Securities has maintained a 'buy' rating and 500p target price for NatWest after the UK bank's better-than-expected fourth-quarter results on Friday, highlighting the "sustainable quality" of the business. NatWest's shares were down more than 3% at 423.5p in afternoon trade despite the company reporting an adjusted pre-tax profit of £1,539m for the fourth quarter, some 13% ahead (£177m) of the consensus forecast of £1,362m.

The beat largely reflected impairments coming in £137m below estimates, though results were still 3% ahead of forecasts when provisions are excluded.

Meanwhile, the company's guidance for 2025 was largely in line with market expectations, but the future dividend payout ratio was lifted to 50% from 40%, putting it towards the top end of the sector.

"We think Q424 results and the new guidance point to a story of sustainable quality. Income ex notable items was 4% ahead, with volume growth continue to be strong - in particular, Commercial and Institutional again grew by c.3% in one quarter (also up c.3% in Q324)," BofA said in a research note.

"While 2025 and 2027 guidance were not significantly ahead of consensus, they demonstrate confidence in the sustainability of returns. The shares are not particularly cheap at 1.2x consensus P/TBV25e, but we see scope for a simple, sustainable mid-teens ROTE bank to continue re-rating."

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.